tirzepatide day 3 3: Mounjaro (Tirzepatide – weekly injection) Class: Dual GLP-1 and GIP receptor agonist Avg Weight Loss: ~20% of baseline weight (SURMOUNT-1 trial) FDA Status: Approved for type 2 diabetes; Fast-tracked for How To Give Your Own

Weight loss drugs have shown impressive short-term results, but new research suggests their benefits may be difficult to sustain once treatment ends

Medical Writing/Editorial Assistance Medical writing support funded by Novo Nordisk A/S was provided by Will Cottam, PhD, of Real-World Evidence, OPEN Health, and by Geraint Roberts, PhD, of Health Economics and Outcomes Research Ltd., in accordance with Good Publication Practice (GPP) guidelines (GPP 2022 [ismpp.org])

Treatments are vehicle (V), cagrilintide (C, 2 nmol/kg), semaglutide (S, 2 nmol/kg), and calorie-restricted to match the weight of the CS rats (weight matched, WM)

That's all marketing

Reaes alrgicas graves